Articles tagged with Type 2 Diabetes
Results from two Phase II studies support the efficacy profile of sitagliptin, a novel DPP-IV inhibitor, improving glycaemic control in patients with type 2 diabetes. Treatment with sitagliptin resulted in no significant weight gain and a low risk of hypoglycaemia.
The PROactive study shows that ACTOS significantly improves cardiovascular outcomes by reducing heart attacks, strokes, and death in high-risk patients. The study found a 16% reduction in life-threatening events and significant improvements in lipid profiles, blood pressure, and insulin resistance.
Research by Yale University found that insulin-resistant individuals' mitochondria produce less ATP, a key energy molecule. This defect may explain the link between inherited type 2 diabetes risk and reduced insulin signaling.
Researchers found that SH2-B regulates leptin sensitivity, energy balance, and body weight in mice, leading to obesity and metabolic syndrome. The study identifies SH2-B as a critical component in maintaining leptin sensitivity, potentially serving as a therapeutic target for treating obesity and type 2 diabetes
Researchers found insulin resistance can be detected 20 years before diabetes symptoms appear in lean, healthy young adults. Mitochondria's energy-producing function is significantly impaired, leading to a decreased ability to burn sugars and fats efficiently.
Researchers at Joslin Diabetes Center have identified a new gene, ARNT, that plays a crucial role in the development of type 2 diabetes. The study, which used DNA chips to analyze islet cells from patients with the disease, found a marked down-regulation of ARNT, suggesting a possible new target for treatment.
Research reveals retinol binding protein 4 (RBP4) plays a key role in developing insulin resistance, a primary risk factor for diabetes. Elevated RBP4 levels correlate with the severity of insulin resistance in humans with obesity or type 2 diabetes.
A new clinical trial has shown that the oral treatment RBX may reduce the risk of moderate vision loss caused by macular edema in patients with type 1 or type 2 diabetes. The study, led by Joslin Diabetes Center, evaluated the safety and effect of RBX on retinopathy progression and visual loss.
A new study found that adult lifestyle, particularly body fat and waist-hip ratio, is a significant risk factor for insulin resistance and Type 2 diabetes. Childhood factors such as birth weight and nutrition have limited impact on the development of insulin resistance in adulthood.
Takeda has submitted a new drug application for its combination type 2 diabetes medication, ACTOS (pioglitazone HCl) and glimepiride. This treatment aims to help patients manage their blood glucose levels by targeting insulin resistance and increasing insulin production.
Research suggests that saturated and trans fats activate a specific potassium channel in the pancreas, increasing blood sugar levels and insulin secretion. People with a specific genetic polymorphism, found in about 2 million Canadians, may be more susceptible to type 2 diabetes if they consume high-fat diets or are overweight.
Researchers identified genetic regions on chromosomes 6, 7, and 19 associated with prediabetes in response to aerobic exercise. The study found that individuals differ in their blood sugar equilibrium after exercise, allowing for unique analysis of insulin sensitivity and glucose metabolism.
A new study found that diabetic patients are at higher risk for developing respiratory tract, skin and mucous membrane, and urinary tract infections. The odds were significantly higher for both type 1 and type 2 diabetic patients compared to non-diabetic controls.
A study found that 46% of children with type 2 diabetes have a history of neuropsychiatric disease, highlighting the need for screening and scrutiny of medications. The researchers suggest that depression and other neuropsychiatric conditions may contribute to the development of type 2 diabetes.
A new approach to managing type 2 diabetes has been demonstrated in a Canadian study, showing that early addition of insulin glargine therapy can safely achieve better glycemic and metabolic outcomes. The results show lower and steady blood glucose levels more quickly and often compared to oral medications.
Researchers discovered that diabetic retinopathy occurs in people with pre-diabetes, suggesting eye changes may begin earlier than previously thought. Regular eye exams and good blood sugar control are recommended to prevent vision loss.
A new study demonstrated add-on effects of ACTOS on diabetic dyslipidemia, reducing triglycerides and increasing HDL cholesterol. Patients with type 2 diabetes who switched from Avandia to ACTOS showed significant improvements in lipid levels, regardless of age or gender.
Researchers found that taking pioglitazone for three years significantly reduced the risk of developing type 2 diabetes in women who had previously had gestational diabetes. This is promising news for preventing and treating type 2 diabetes, as it may help stabilize beta-cell function.
A study found that ACTOS reduced inflammation markers CRP and IL-6, improving glycemic control in patients with stable blood sugar levels. Treatment with ACTOS resulted in significant decreases in these markers compared to placebo.
A study found that resistance training significantly improved blood sugar levels in older Hispanic adults with type 2 diabetes. The participants who underwent 16 weeks of resistance training showed a substantial reduction in body fat and increase in muscle mass, similar to the effects seen when weight loss is achieved through other means.
The study reveals that type 2 diabetes now accounts for up to 45% of new cases among adolescents globally. Rising obesity rates are particularly alarming in certain ethnic groups, including Native Americans and Pima Indians, who have the world's highest recorded rate of Type 2 diabetes.
A recent study found that men consuming higher levels of low-fat dairy products have a significantly lower risk of developing type 2 diabetes. The researchers analyzed data from over 41,000 participants and found that each serving per day of low-fat dairy intake resulted in a 9% reduction in the risk of developing the disorder.
A recent study published in Archives of Internal Medicine found that consuming low-fat dairy products was associated with a nine percent lower risk of developing type 2 diabetes in male participants. The researchers analyzed data from over 41,000 men and followed them for 12 years to document new cases of type 2 diabetes.
Researchers discovered that FGF-21 regulates glucose uptake in human fat cells, significantly reducing plasma glucose levels and triglycerides. FGF-21 also protected animals from diet-induced obesity, providing evidence for its therapeutic potential in treating type 2 diabetes.
Researchers found that a fiber supplement significantly decreased LDL and increased HDL cholesterol levels in people with type 2 diabetes. The study suggests an alternative treatment option for those unable or unwilling to take statins.
A new study found that the ENPP1 gene variant is associated with an increased risk of developing type 2 diabetes. The variant, which affects insulin action, was more common in people with type 2 diabetes and those at high risk for the disease, regardless of ethnicity.
Researchers found that the MIF gene is crucial for the development of type 1 diabetes. Specially bred mice without the gene failed to develop diabetes compared to those with it. The finding provides proof of concept for blocking the formation of this protein as a promising approach to fighting diabetes.
A new study by Johns Hopkins Bloomberg School of Public Health reveals that larger waist sizes and higher body fat are strongly associated with an increased risk of developing type 2 diabetes in adult men. The researchers recommend measuring waist circumference instead of waist-to-hip ratio to assess health risk.
Researchers discovered that low-carbohydrate diets led to spontaneous reduction in daily energy consumption and improved glucose levels in obese diabetic patients. The study found no evidence of boredom or metabolic changes as explanations for weight loss.
Research at Joslin Diabetes Center reveals that prenatal undernutrition can lead to impaired insulin production and higher blood glucose levels, setting the stage for type 2 diabetes. The study found that low-birth-weight mice had abnormal insulin secretion patterns, leading to permanent impairment.
Researchers at Joslin Diabetes Center have identified the critical role of two insulin signaling proteins in controlling glucose and lipid metabolism. By knocking out these proteins in liver cells, they found that diabetes results when both signals are simultaneously low, but not when either is individually depleted.
A recent study revealed that nearly one-third of diabetic men suffer from hypogonadism, a condition caused by improper functioning of the pituitary gland or hypothalamus. The high prevalence of low testosterone levels in diabetic patients is concerning and associated with various health issues such as loss of muscle tone, increased abd...
A recent study by Charlotte Ling and colleagues found that aging decreases the expression of PGC-1alpha and PGC-1beta in muscle, increasing insulin resistance and T2DM susceptibility. The age-dependent decrease was partially heritable, suggesting a genetic link to the development of insulin resistance.
A new study examined ACTOS and Avandia's lipid-altering effects in patients with type 2 diabetes. The results suggest looking beyond glycemic effects to potential lipid benefits, which could inform treatment strategies.
Researchers found that pioglitazone significantly reduced carotid artery thickness in just 12-24 weeks, while improving insulin resistance. This regression was independent from metabolic control improvements and correlated with better cardiovascular outcomes for patients with type 2 diabetes.
A study found that people with type 2 diabetes are not being optimally managed for their cardiovascular risk. Fewer than 25% of patients were on medication needed to control high cholesterol and less than 50% received treatment for high blood pressure.
A study of 1,148 hypertensive patients with type 2 diabetes found that tight blood pressure control reduced the incidence of diabetic retinopathy and visual loss by 47% over seven years. The researchers discovered a lower risk of microaneurysms and blindness in the tight BP control group compared to those with less stringent policies.
Dr. von Andrian will focus on setting up a new microscopy model at Joslin to study the interaction between islet cells and immune cells, aiming to develop a simple model for studying islet cells in living animals. He will also collaborate with Joslin researchers on stem cell projects and vascular complications in people with diabetes.
A 12-week physical activity program will be implemented and evaluated in 16 worksites across the US and Canada to assess its effectiveness on promoting physical activity among employees. The study aims to determine the effects of a multilevel intervention aimed at personal goal-setting and ecologically based organizational action.
Crestor demonstrates improved lipid profiles and lower LDL-C targets than atorvastatin, achieving higher patient success rates with fewer doses. Crestor also shows effectiveness in reducing apolipoprotein B levels and improving the Apo B:Apo A-I ratio.
Researchers identified a gene called PTPN1 that represses insulin response and is associated with diabetes. The study found a common variant of the gene increases the risk of diabetes in Caucasians, while another form appears protective.
A new gene marker has been found to increase the risk of heart disease in people with type 2 diabetes. The CD36 gene variant is associated with higher levels of free fatty acids and triglycerides, leading to a 60% increased risk of heart disease.
A pilot study dubbed STAND UP! aims to monitor food intake and physical activity in schools to reduce risk factors for type 2 diabetes among sixth-graders. The program's results will be used to improve the intervention before expanding it to middle schools nationwide.
A three-month study found that patients with type 2 diabetes preferred the prefilled NovoLog(R) Mix 70/30 FlexPen(R) disposable pen due to its ease of use and flexibility. Patients who had never used insulin before reported significant benefits in perceived clinical efficacy.
A significant social gradient in the incidence of type 2 diabetes was observed among civil servants, with men and women in lower employment grades having a higher risk of developing the disease. Effort-reward imbalance was also found to be associated with an increased risk of type 2 diabetes in men.
A study of 91,249 women found a strong association between frequent consumption of sugar-sweetened beverages and increased risk of type 2 diabetes. Women who consumed more sugar-sweetened drinks experienced greater weight gain and higher risk of developing the condition.
Diabetics are susceptible to prolonged inflammation due to infection, leading to cardiovascular disease and poor wound healing. Inhibiting excess TNF may reduce the tendency for prolonged inflammation.
A study found that atorvastatin reduced cardiovascular events, deaths, and strokes by a third in patients with type 2 diabetes without high LDL cholesterol. The results suggest statin therapy may be safe and effective for this patient group.
A new study shows that consuming isolated soy protein can slow down the progression of diabetic kidney disease and improve coronary heart disease in patients with type 2 diabetes. The study found a significant reduction in urinary albumin levels and an improvement in HDL cholesterol levels among participants who consumed soy protein.
A UK study found that a significant proportion of people with type 2 diabetes are managed solely through diet, receiving inadequate monitoring and care. This highlights the need for better routine surveillance and consistency in clinical practice to address the high rate of complications among these patients.
Research finds connection between cytokine IL-4 signaling impairment and type 2 diabetes. Hyperinsulinemia triggers serine phosphorylation, impacting insulin receptor substrates and leading to neuroimmune response.
A meta-analysis found that fluoxetine, orlistat, and sibutramine can achieve modest but statistically significant short-term weight loss in adults with type 2 diabetes. Levels of glycated hemoglobin were also modestly reduced by the medications.
The PROactive study assesses the effect of ACTOS on cardiovascular disease progression in patients with type 2 diabetes. The study examines whether pioglitazone reduces cardiovascular mortality and morbidity in a high-risk population.
A recent study published in the Proceedings of the National Academy of Sciences found that overexpressing a selenium-containing enzyme in mice led to insulin resistance and obesity. The researchers suggest that antioxidants, like selenium, may be harmful by neutralizing free radicals necessary for insulin signaling.
ACTOS therapy has favorable effects on dyslipidemia, including reductions in triglycerides and increases in HDL cholesterol. Additionally, ACTOS was found to have beneficial effects on non-HDL cholesterol and A1C levels.
A study of 3,140 patients found pioglitazone to lower blood pressure in both Stage I and Stage II hypertension cases. This effect could reduce cardiovascular disease risk factors in patients with type 2 diabetes.
Studies presented at the American Diabetes Association annual meeting showed ACTOS to be effective in reducing fasting insulin levels and improving A1C levels, with significant benefits seen when used alone or in combination with other oral antidiabetic medications.
The CARDS trial found that a daily 10mg dose of atorvastatin reduced the risk of serious heart problems by 36% and strokes by 48%. The benefits were observed even in patients with already low LDL-cholesterol levels. This study has significant implications for the cardiovascular health of people with Type 2 diabetes.
A landmark UK study sponsored by Diabetes UK, Department of Health, and Pfizer UK showed that 10mg atorvastatin reduced cardiovascular events by 37% in patients with diabetes without existing CVD. Stroke was substantially reduced by 48% in these patients.
Over 60% of type 2 diabetes patients fail to meet recommended glucose treatment goals, increasing risk of complications such as heart disease and blindness. The Control to Goal initiative aims to bridge the gap between guidelines and clinical practice, promoting better diabetes management.